Caris Life Sciences, Inc. (CAI) Q4 FY25 Earnings Call

Strong profitable growth funds major commercial and early-detection investments, but 2026 guidance excludes pipeline revenue.

Q4 FY25 results, source: company transcript and SEC filings
QuarterQ4 FY25
Call date2026-02-28
Length61 minutes
EPS$0.28
Revenue$216.8M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

All CAI earnings ยท Back to CAI overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.